Latest filings (excl ownership)
15-12G
Securities registration termination
8 Jan 24
EFFECT
Notice of effectiveness
3 Jan 24
EFFECT
Notice of effectiveness
3 Jan 24
POS AM
Prospectus update (post-effective amendment)
27 Dec 23
POS AM
Prospectus update (post-effective amendment)
27 Dec 23
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Dec 23
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Dec 23
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Dec 23
25-NSE
Exchange delisting
27 Dec 23
8-K
Termination of a Material Definitive Agreement
27 Dec 23
SC 14D9/A
Tender offer solicitation (amended)
22 Dec 23
SC TO-T/A
Third party tender offer statement (amended)
22 Dec 23
SC 14D9/A
Tender offer solicitation (amended)
18 Dec 23
SC TO-T/A
Third party tender offer statement (amended)
18 Dec 23
SC 14D9/A
Tender offer solicitation (amended)
4 Dec 23
SC TO-T/A
Third party tender offer statement (amended)
4 Dec 23
SC 14D9/A
Tender offer solicitation (amended)
17 Nov 23
SC TO-T/A
Third party tender offer statement (amended)
17 Nov 23
SC 14D9/A
Tender offer solicitation (amended)
15 Nov 23
SC TO-T/A
Third party tender offer statement (amended)
15 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
SC 14D9/A
Tender offer solicitation (amended)
8 Nov 23
SC TO-T/A
Third party tender offer statement (amended)
8 Nov 23
SC 14D9/A
Tender offer solicitation (amended)
1 Nov 23
SC 14D9/A
Tender offer solicitation (amended)
27 Oct 23
SC TO-T/A
Third party tender offer statement (amended)
27 Oct 23
SC 14D9
Tender offer solicitation
13 Oct 23
SC TO-T
Third party tender offer statement
13 Oct 23
SC14D9C
Written communication relating to third party tender offer
3 Oct 23
SC TO-C
Information about tender offer
3 Oct 23
SC14D9C
Written communication relating to third party tender offer
3 Oct 23
8-K
Tender and Support Agreement
3 Oct 23
S-8
Registration of securities for employees
14 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
14 Aug 23
8-K
Changes in Registrant's Certifying Accountant
3 Aug 23
8-K
Departure of Directors or Certain Officers
13 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
5 Jun 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
Latest ownership filings
4
JONATHAN R. GOODMAN
27 Dec 23
4
JUSTYNA KELLY
27 Dec 23
4
JOE A. MCCANN
27 Dec 23
4
JESSICA D. JENSEN
27 Dec 23
4
NEIL E. FLESHNER
27 Dec 23
4
GERALD L. HOGUE
27 Dec 23
4
Rajesh Malik
27 Dec 23
4
David Charles Lubner
27 Dec 23
4
WILLIAM L. DEMERS
27 Dec 23
4
ALLAN C SILBER
27 Dec 23
4
YAEL MARGOLIN
27 Dec 23
SC 13D/A
SILBER ALLAN C
27 Dec 23
4
MARK N LAMPERT
20 Dec 23
SC 13D/A
BIOTECHNOLOGY VALUE FUND L P
20 Dec 23
4
JOE A. MCCANN
7 Nov 23
4
ALLAN C SILBER
7 Nov 23
3
MARK N LAMPERT
6 Nov 23
SC 13D
BIOTECHNOLOGY VALUE FUND L P
6 Nov 23
4
NEIL E. FLESHNER
2 Nov 23
SC 13D/A
SILBER ALLAN C
3 Oct 23
4
Bridget A Martell
14 Jun 23
3
Bridget A Martell
14 Jun 23
4
GERALD L. HOGUE
5 Jun 23
4
JONATHAN R. GOODMAN
5 Jun 23
4
YAEL MARGOLIN
5 Jun 23
4
Rajesh Malik
5 Jun 23
4
David Charles Lubner
5 Jun 23
4
ALLAN C SILBER
30 Mar 23
4
JOE A. MCCANN
30 Mar 23
4
JUSTYNA KELLY
30 Mar 23
4
JESSICA D. JENSEN
30 Mar 23
4
NEIL E. FLESHNER
30 Mar 23
4
WILLIAM L. DEMERS
30 Mar 23
4
GERALD L. HOGUE
23 Mar 23
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 23
SC 13G
BlackRock Inc.
3 Feb 23
4
JOE A. MCCANN
30 Nov 22
4
David Charles Lubner
28 Nov 22
4
GERALD L. HOGUE
28 Nov 22
4
Rajesh Malik
28 Nov 22